Nisa Investment Advisors LLC bought a new stake in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 11,470 shares of the company’s stock, valued at approximately $221,000.
A number of other large investors have also made changes to their positions in AMPH. Cubist Systematic Strategies LLC bought a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter worth $295,000. Renaissance Technologies LLC boosted its position in shares of Amphastar Pharmaceuticals by 76.6% in the 2nd quarter. Renaissance Technologies LLC now owns 91,100 shares of the company’s stock worth $1,390,000 after purchasing an additional 39,500 shares during the last quarter. Federated Investors Inc. PA boosted its position in shares of Amphastar Pharmaceuticals by 21.6% in the 2nd quarter. Federated Investors Inc. PA now owns 1,276,552 shares of the company’s stock worth $19,480,000 after purchasing an additional 227,142 shares during the last quarter. Cortina Asset Management LLC boosted its position in shares of Amphastar Pharmaceuticals by 49.9% in the 2nd quarter. Cortina Asset Management LLC now owns 392,296 shares of the company’s stock worth $5,986,000 after purchasing an additional 130,604 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Amphastar Pharmaceuticals by 5.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,769,533 shares of the company’s stock worth $27,004,000 after purchasing an additional 84,085 shares during the last quarter. Hedge funds and other institutional investors own 43.33% of the company’s stock.
Several research firms have recently issued reports on AMPH. Zacks Investment Research upgraded Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 10th. ValuEngine upgraded Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 10th. BidaskClub upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 9th. Finally, Needham & Company LLC reduced their price target on Amphastar Pharmaceuticals from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday, August 10th. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $21.40.
In related news, CFO William J. Peters sold 2,407 shares of the firm’s stock in a transaction on Thursday, August 16th. The stock was sold at an average price of $17.59, for a total transaction of $42,339.13. Following the sale, the chief financial officer now owns 86,836 shares of the company’s stock, valued at approximately $1,527,445.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Richard K. Prins sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $17.82, for a total value of $178,200.00. The disclosure for this sale can be found here. Company insiders own 31.50% of the company’s stock.
Shares of Amphastar Pharmaceuticals stock opened at $18.44 on Friday. The firm has a market cap of $844.64 million, a P/E ratio of 121.73, a price-to-earnings-growth ratio of 8.32 and a beta of 1.42. Amphastar Pharmaceuticals Inc has a 12 month low of $14.40 and a 12 month high of $20.45. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.24 and a current ratio of 1.94.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, August 8th. The company reported $0.03 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.08 by ($0.05). The business had revenue of $71.00 million for the quarter, compared to analyst estimates of $64.22 million. Amphastar Pharmaceuticals had a positive return on equity of 2.15% and a negative net margin of 3.39%. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.11 EPS. On average, analysts expect that Amphastar Pharmaceuticals Inc will post 0.1 EPS for the current year.
Amphastar Pharmaceuticals Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
See Also: Average Daily Trade Volume Explained
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.